Researchers have created a next-generation obesity drug that works like a “Trojan horse,” using GLP-1/GIP signals to slip a powerful metabolic enhancer directly into target cells. In mice, it outperformed existing treatments—curbing appetite, increasing weight loss, and improving blood sugar levels. Because the extra drug acts only where it’s needed, it can be used at much lower doses, potentially
Some people taking Ozempic-like diabetes drugs may be getting dramatically better results for a surprising reason: why they overeat in the first place. A year-long study in Japan found that people who tend to eat because tempting food looks or smells irresistible were much more likely to lose weight and improve blood sugar levels on GLP-1 medications. But people who eat mainly in response to stres
Aging doesn’t just add fat—it redistributes it in risky ways, pushing more into the abdomen where it can harm health. Scientists found that testosterone plays a key role in this shift. In older women recovering from hip fractures, a testosterone gel combined with exercise helped prevent the usual rise in dangerous visceral fat. The result could point to a powerful new strategy for improving recove
The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.
Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.
Scientists in Sweden have taken a major step toward a potential cure for type 1 diabetes by developing a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice.
Faced with stiff local opposition and a possible loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.
Administration report on most-favored nation drug pricing raises new details — and questions.
Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.
Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.
Marty Makary says he was "skeptical initially" about flavored vapes but that age-gating technology could limit their use.
The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat.
In a bid to better deploy its boots-on-the-ground resources, the FDA is rolling out a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to complement its traditional site visits.
After several consecutive quarters on the backfoot, Danish drug juggernaut Novo Nordisk is receiving warmer feedback on its starting performance in 2026, thanks in no small part to its head start over rival Eli Lilly in the burgeoning market for oral obesity therapies.
The FDA-conducted studies reportedly found COVID vaccines and GSK's shingles vaccine Shringrix safe and effective, according to The New York Times.
Cell and gene therapy developers must build continuity of engagement to create trust in the modalities, according to a report by Bayer’s venture capital wing.
Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administration released a report Tuesday projecting potential $529 billion in savings from the policy over the next 10 years.
Last month, when Optimi Health kicked off an initial public offering of 2.5 million shares, the timing couldn’t have been better for the Vancouver-based manufacturer of psychedelic drugs. With President Donald Trump recently signing an executive order to accelerate research and ease the restrictions on psychedelics, there is unprecedented buzz around the potential of the hallucinogenic drugs to tr
As the promotion battle between old rivals Novo Nordisk and Eli Lilly heats up, regulators in France are reminding the world’s two biggest obesity drugmakers what happens when promotion goes too far.